Hospira, Inc. Phasing Out Troubled Infusion Pumps

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Hospira Inc. on Wednesday said it will phase out a handful of its drug infusion pumps after receiving a notice from the Food and Drug Administration questioning the quality of those devices. The Lake Forest-based maker of injectable drugs and infusion equipment said it will spend between $300 million and $350 million to do away with its Symbiq, GemStar, older Plum brand pumps and a host of other legacy pumps over the next two to three years and invest in the development of replacements. In February, Hospira warned it could incur "significant" costs in restructuring and modernizing its device business, on top of millions the company has spent fixing problems.

Help employers find you! Check out all the jobs and post your resume.

Back to news